Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by stockman6767on Oct 27, 2016 1:13pm
362 Views
Post# 25393529

Here is Fred's response to my OFF-LABEL thought.

Here is Fred's response to my OFF-LABEL thought.Hi ......,
 
There is always off-label usage even though as a company we will not promote such usage. Our goal is to have plasminogen established as an hospital product used in many different indications. We will provide more information on our plan for Pg at the analyst day. We have developed a different formulation already for wound healing and it will be used in the upcoming wound healing trial in Sweden. For hard to treat wounds, as you know there will be micro-injection of Pg in small quantities, intra-dermal around the wound. More to come on the study protocol once the CTA is cleared. We will not even try to quantify sales for indications not yet approved or off-label usage.
 
Thx
 
Regards
 
Fred
 
Frdric Dumais, B. Comm., LLB.
 
Directeur principal, Communications et relations avec les investisseurs
Senior Director, Communications and Investor Relations
 
ProMetic Sciences de la Vie inc.
ProMetic Life Sciences Inc.
Bullboard Posts